Evotec SE Investor Presentation — July 2024

Document content

70.6%43.0%72.2%61.5%84.5%83.1%79.0%

16.1%14.0%47.0%22.4%7.1%28.0%

0% 20% 40% 60% 80% 100%HMPL-523(Ph1)FostamatinibEfgartigimodRilzabrutinib[3]HetrombopagRomiplostimEltrombopag

48.4%18.0%21.8%35.0%39.9%43.8%49.0%60.0%

0.0%2.0%5.0%0.0%2.0%10.0%

0% 20% 40% 60% 80% 100%Sovleplenib(Ph1)FostamatinibEfgartigimodRilzabrutinib[3]HetrombopagAvatrombopagRomiplostimEltrombopag